文献速递特殊人群用药药物不良反应与药物警戒

美泊利珠单抗妊娠暴露研究的挑战与启示

Challenges and Insights from the Mepolizumab Pregnancy Exposure Study.
PubMed 文献 · Drug Saf · 2026-09-03

美泊利珠单抗上市时妊娠安全性数据有限,2016年启动前瞻性观察性妊娠暴露登记研究,比较暴露组与抗哮喘治疗组及无哮喘孕妇,但5年入组期暴露组招募不足,研究于2024年关闭。文章讨论挑战并提出低暴露场景下强化药物警戒的实用决策框架。

要点

  • 美泊利珠单抗妊娠暴露登记研究因暴露组入组不足于2024年关闭。
  • 抗哮喘比较组入组充分,提示可招募哮喘孕妇但美泊利珠单抗妊娠期使用有限。
  • 低暴露时强化药物警戒可作为注册研究不可行时的务实监测工具。

核心结论

  • 美泊利珠单抗妊娠暴露研究因暴露组招募不足而关闭,凸显低暴露药物妊娠安全性研究的可行性挑战。
  • 在人群暴露率低、注册或数据库研究不可合理开展时,强化药物警戒是更稳健的结构化数据收集方法。
  • 强化药物警戒难以得出确定性安全性结论,但可作为其他研究设计可行前的持续监测工具。

研究设计与样本

  • 美泊利珠单抗妊娠暴露研究(GSK ID: 200870;EU PAS Number: EUPAS13772)为IV期前瞻性观察性暴露登记研究。
  • 研究由畸形学信息专家组织(OTIS)研究中心于2016年启动。
  • 研究比较暴露于美泊利珠单抗的孕妇与接受其他抗哮喘治疗孕妇及无哮喘孕妇,评估潜在致畸效应。
  • 入组期为5年,最终于2024年因招募不足关闭。

主要发现

  • 尽管广泛招募,美泊利珠单抗暴露队列在5年入组期内入组人数持续偏低。
  • 抗哮喘比较队列实现了稳健入组,表明可招募哮喘孕妇且美泊利珠单抗妊娠期使用有限。

临床怎么用

  • 对低暴露药物的妊娠安全性监测,可考虑强化药物警戒以结构化收集重要变量和混杂因素。
  • 强化药物警戒应作为持续监测的务实必要工具,直至更稳健研究设计可行。

局限性

  • 药物警戒在生成确定性安全性结论方面存在固有局限性。
  • 美泊利珠单抗妊娠暴露研究因暴露组招募不足而关闭,未能按计划完成比较评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pregnant women are often excluded from clinical trials owing to uncertainty about fetal safety and adverse pregnancy complications. As such, little is known about the effect of medications on pregnancy at the time of marketing. Post-marketing data are therefore important for establishing the safety of treatments in pregnancy, particularly in chronic diseases requiring long-term therapy. Mepolizumab (NUCALA), a first-in-class biologic treatment for patients with severe eosinophilic asthma, was first approved in the United States (US) and European Union (EU) in 2015 as an add-on maintenance treatment for adult and adolescent patients. At the time of marketing, pregnancy safety data for mepolizumab was limited. To address this gap, a Post-Authorization Safety Study (PASS) was conducted-a pregnancy registry to monitor pregnancies exposed to mepolizumab and evaluate the possible teratogenic effect of this medication compared with women treated with other anti-asthmatics and those without asthma. The Mepolizumab Pregnancy Exposure Study (GSK ID: 200870; EU PAS Number: EUPAS13772), a phase IV, prospective, observational exposure registry, was initiated in 2016 by the Organization of Teratology Information Specialists (OTIS) Research Center. Despite extensive recruitment efforts, enrollment into the mepolizumab-exposed cohort remained low during the 5-year enrollment period. In contrast, robust enrollment in the anti-asthmatic comparison cohort was achieved, suggesting both the ability to recruit pregnant women with asthma and the limited use of mepolizumab in pregnancy. The Mepolizumab Pregnancy Exposure Study was ultimately closed in 2024 due to inadequate recruitment. This commentary presents the challenges experienced in the Mepolizumab Pregnancy Exposure Study and describes a pragmatic decision-making framework aimed at mitigating similar issues in future post-marketing pregnancy safety studies, particularly in the context of low treatment exposure in individual population-level data sources. This framework considers important inputs such as prior experience with treatment in the same therapeutic area, background maternal and fetal risks, and potential treatment utilization in the population of interest. A principal recommendation stemming from this framework is the implementation of enhanced worldwide pharmacovigilance, which offers a more robust and structured approach to data collection than standard pharmacovigilance methods, thereby improving information quality and enabling the capture of important variables and confounders, when the exposure rate is low in a population and registry or other database studies cannot reasonably be conducted. However, given the inherent limitations of pharmacovigilance in generating definitive safety conclusions, enhanced data collection methods serve as a pragmatic and necessary tool for ongoing surveillance, to aid in providing information until other types of study designs becoming feasible. Mepolizumab, an injectable treatment for severe eosinophilic asthma, had limited safety information in pregnant women at time of marketing. To address this crucial gap, the Mepolizumab Pregnancy Exposure Study, a Post-Authorization Safety Study was initiated in 2016. This registry aimed to monitor pregnancies exposed to mepolizumab compared with women treated with other anti-asthmatics and those without asthma. Despite significant recruitment efforts, enrollment into the mepolizumab-treated group remained low over the 5-year enrollment period, leading to its closure in 2024. This low recruitment highlighted two things: pregnant women with asthma could successfully be recruited and the limited use of mepolizumab in pregnancy. This article discusses the challenges experienced in the Mepolizumab Pregnancy Exposure Study and describes a practical decision-making framework for post-marketing pregnancy safety studies. This framework considers important factors such as prior experience with similar treatments, background maternal and fetal risks, and potential treatment utilization in the population of interest. For scenarios of low treatment exposure in individual population-level data sources, a key recommendation is enhanced pharmacovigilance as a more robust and structured way of collecting safety information than standard methods. While these methods rarely establish definitive safety conclusions, they are a practical and necessary tool until more robust study designs become feasible.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Wurst KE, Schatz M, Kumar S, et al. Challenges and Insights from the Mepolizumab Pregnancy Exposure Study. Drug Saf. 2026. PMID: 42690284. doi:10.1007/s40264-026-01724-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。